Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 562-570

  Messmann, Richard A ^a   Ullmann, Claudio Dansky ^b   Lahusen, Tyler ^c   Kalehua, Audrey ^b   Wasfy, Jason ^a   Melillo, Giovanni ^a   Ding, Ivan ^d   Headlee, Donna ^a   Figg, William D ^a   Sausville, Edward A ^a   Senderowicz, Adrian M ^a,c  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c National Institute of Aging   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BASIC FIBROBLAST GROWTH FACTOR; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; FLAVOPIRIDOL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEVER; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROINFLAMMATORY SYNDROME; WILCOXON SIGNED RANKS TEST;

ANTINEOPLASTIC AGENTS; BONE MARROW; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; INFLAMMATION; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; INTERLEUKINS; NEOPLASMS; PIPERIDINES;

EID: 0037317194     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Senderowicz, A. M. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene. 19: 6600-6606, 2000.
2. Senderowicz, A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New Drugs, 17: 313-320, 1999.
3. Singh, S. S., Sausville E. A., and Senderowicz A. M. Cyclin DI and Cdk6 are the targets for flavopiridol-mediated G1 block in MCF10A MC1710A breast epithelial cell line. Philadelphia: Proc. Ninetieth Annual Meeting of the American Association of Cancer Res., 1999.
4. Carlson, B. A., Dubay, M. M., Sausville, E. A., Brizuela, L., and Worland. P. J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
5. Patel, V., Senderowicz, A. M., Pinto, D., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., and Gutkind, J. S. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Investig., 102: 1674-1681, 1998.
6. Parker, B., Kaur, G., Nieves-Neira, W., Taimi, M., Kolhagen, G., Shimizu, T., Pommier, Y., Sausville, E., and Senderowicz, A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91: 458-465, 1998.
7. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sausville, E. A., and Senderowicz, A. M. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 59: 4634-4641, 1999.
8. Melillo, G., Sausville, E. A., Cloud, K., Lahusen, T., Varesio, L., and Senderowicz, A. M. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res., 59: 5433-5437, 1999.
9. Gray, N. S., Wodicka, L., Thunnissen, A. M., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., Kim, S. H., Lockhart, D. J., and Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science, 281: 533-538, 1998.
10. Chao, S. H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., and Price, D. H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem., 275: 28345-28348, 2000.
11. Wright, J., Blamer, G. L., and Cheson, B. D. Clinical trials referral resource. Clinical trials of flavopiridol. Oncology (Huntingt), 12: 1018, 1023-1024, 1998.
12. Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., and Vokes, E. E. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II consortium study. J. Clin. Oncol., 18: 371-375, 2000.
13. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-2999, 1998.
14. Thomas, J., Cleary, J., Tutsch, K., Arzoomanian, R., Alberti, D., Simon, K., Feierabend, D., Morgan, K., and Wilding, G. Phase I clinical and pharmacokinetic trial of flavopiridol, San Diego: Proc. Eightieth Annual Meeting of the American Association of Cancer Res., 1997.
15. Gabay, C., and Kushner, I, Acute-phase proteins and other systemic responses to inflammation (Published erratum in N. Engl. J. Med., 340: 1376, 1999). N. Engl. J. Med., 340: 448-454, 1999.
16. Baumann, H., and Gauldie, J. The acute phase response. Immunol. Today, 15: 74-80, 1994.
17. Koj, A. Initiation of acute phase response and synthesis of cytokines. Biochim. Biophys. Acta, 1317: 84-94, 1996.
18. Trey, J. E., and Kushner, I. The acute phase response and the hematopoietic system: the role of cytokines. Crit. Rev. Oncol. Hematol., 21: 1-18, 1995.
19. Dong, C., and Flavell, R. A. Th1 and Th2 cells. Curr. Opin. Hematol., 8: 47-51, 2001.
20. Rubinstein, M., Dinarello, C. A., Oppenheim, J. J., and Hertzog, P. Recent advances in cytokines, cytokine receptors and signal transduction. Cytokine Growth Factor Rev., 9: 175-181, 1998.
21. Begley, C. G., and Nicola, N. A. Resolving conflicting signals: cross inhibition of cytokine signaling pathways. Blood, 93: 1443-1447, 1999.
22. Viola, J. P., and Rao, A. Molecular regulation of cytokine gene expression during the immune response. J. Clin. Immunol., 19: 98-108, 1999.
23. Dinarello, C. A. Proinflammatory cytokines. Chest, 118: 503-508, 2000.
24. Arguello, F., Alexander, M., Sterry, J., Tudor, G., Smith, E., Kalavar, N., Greene, J., Koss, W., Morgan, D., Stinson, S., Siford, T., Alvord, W., Labansky, R., and Sausville, E. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppresion, and has potent antitumor activity in vivo against human and leukemia xenografts. Blood, 91: 2482-2490, 1998.
25. Bible, K. C., and Kaufmann, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
26. Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., and Grever, M. R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood, 92: 3804-3816, 1998.
27. De Azevedo, W. F., Jr., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93: 2735-2740, 1996.
28. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. (Bethesda), 84: 1736-1740, 1992.
29. Li, Y., Bhuiyan, M., Alhasan, S., Senderowicz, A. M., and Sarkar, F. H. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin. Cancer Res., 6: 223-229, 2000.
30. Senderowicz, A. M., Messmann, R., Arbuck, S., Headlee, D., Zhai, S., Murgo, A., Melillo, G., Figg, W., and Sausville, E. A Phase I trial of 1 hour infusion of flavopiridol (Fla), a novel cyclin-dependent kinase inhibitor, in patients with advanced neoplasms. New Orleans: Proc. Ann. Meet. Am. Soc. Clin. Oncol., 2000.
31. Senderowicz, A., Murgo, A., and Kalil, N. Preclinical and clinical development of Protein serine-threonine Kinase inhibitors. South American Journal of Cancer, 3: 95-112, 2000.
32. Tan, A., Headlee, D., Messmann, R., Sausville, E. A., Arbuck, S., Murgo, A., Melillo, G., Zhai, S., Figg, W., Swain, S., and Senderowicz, A. M. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J. Clin. Oncol., 20: 4074-4082, 2002.
33. Taga, T., and Kishimoto, T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol., 15: 797-819, 1997.
34. Akira, S., Taga, T., and Kishimoto, T. Interleukin-6 in biology and medicine. Adv. Immunol., 54: 1-78, 1993.
35. van Gameren, M. M., Willemse, P. H., Mulder, N. H., Limburg, P. C., Groen, H. J., Vellenga, E., and de Vries, E. G. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood, 84: 1434-1441, 1994.
36. Veldhuis, G. J., Willemse, P. H., Sleijfer, D. T., van der Graaf, W. T., Groen, H. J., Limburg, P. C., Mulder, N. H., and de Vries, E. G. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer, J. Clin. Oncol., 13: 2585-2593, 1995.
37. Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S., Rockett, H., Talbot, D. C., Ganesan, T., Pettit, G. R., Balkwill, F. et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo, The Cancer Res. Campaign Phase I Committee. J. Natl. Cancer Inst. (Bethesda), 85: 1812-1818, 1993.
38. Jayson, G. C., Crowther, D., Prendiville, J., McGown, A. T., Scheid, C., Stern, P., Young, R., Brenchley, P., Chang, J., Owens, S. et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer, 72: 461-468, 1995.
39. Jarvis, W. D., and Grant, S. Protein kinase C targeting in antineo-plastic treatment strategies. Investig. New Drugs, 17: 227-240, 1999.
40. Sosman, J. A., Aronson, F. R., Sznol, M., Atkins, M. B., Dutcher, J. P., Weiss, G. R., Isaacs, R. E., Margolin, K, A., Fisher, R. I., Ernest, M. L., Mier, J., Oleksowicz, L., Eckhardt, J. R., Levitt, D., and Doro-show, J. H. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin. Cancer Res., 3: 39-46, 1997.
41. Weber, J., Gunn, H., Yang, J., Parkinson, D., Topalian, S., Schwartzentruber, D., Ettinghausen, S., Levitt, D., and Rosenberg, S. A. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J. Immunother. Emphas. Tumor Immunol., 15: 292-302, 1994.
42. Weber, J., Yang, J. C., Topalian, S. L., Parkinson, D. R., Schwartzentruber, D. S., Ettinghausen, S. E., Gunn, H., Mixon, A., Kim, H., Cole, D., et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol., 11: 499-506, 1993.
43. Gordon, M. S., Nemunaitis, J., Hoffman, R., Paquette, R. L., Rosenfeld, C., Manfreda, S., Isaacs, R., and Nimer, S. D. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood, 85: 3066-3076, 1995.
44. Blackwell, T. S., and Christman, J. W. The role of nuclear factor-kappa B in cytokine gene regulation. Am. J. Respir. Cell Mol. Biol., 17: 3-9, 1997.
45. Baldwin, A. S., Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol., 14: 649-683, 1996.
46. Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., and Nabel, G. J. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science, 275: 523-527, 1997.
47. Kyriakis, J. M., and Avruch, J. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays, 18: 567-577, 1996.
48. Wysk, M., Yang, D. D., Lu, H. T., Flavell, R. A., and Davis, R. J. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc. Natl. Acad. Sci. USA, 96: 3763-3768, 1999.
49. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 372: 739-746, 1994.
50. Lahusen, J., Loaiza-Perez, A., Sausville, E. A., and Senderowicz, A. M. Flavopiridol-induced apoptosis is associated with p38 and MEK activation and is prevented by caspase and MAPK inhibitors. San Francisco: Proc. Twentieth Ann. Meet. Am. Assoc. Cancer Res., 2000.
51. Chen, L., Mory, Y., Zilberstein, A., and Revel, M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proc. Natl. Acad. Sci. USA, 85: 8037-8041, 1988.
52. Mule, J. J., McIntosh, J. K., Jablons, D. M., and Rosenberg, S. A. Antitumor activity of recombinant interleukin 6 in mice. J. Exp. Med., 171: 629-636, 1990.
53. Ullmann, C. D., Schlom, J., and Greiner, J. W. Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells. J. Immunother., 12: 231-241, 1992.
54. Anderson, K. C. Multiple myeloma. Advances in disease biology: therapeutic implications. Semin. Hematol., 38: 6-10, 2001.
55. Salem, M., Elbaz, O., Zahran, M., Elbaz, A., Elgamal, S., Eteba, S., and Mahmoud, L. A. Malignancy: identification of predictors of disease status and progression in patients with myeloma (MM). Hematology, 5: 41-45, 2000.